According to a recent LinkedIn post from Forge Biologics, the company participated in discussions at the Alliance for Regenerative Medicine’s CGMed26 meeting focused on cell and gene therapy trends in Europe. The post notes that Taleen Barsoumian described Forge’s work with European adeno-associated virus, or AAV, developers across the value chain.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights services ranging from early research-grade manufacturing to global regulatory support, including experience with successful clinical trial applications in the U.K. and under the EU’s Clinical Trials Regulation. For investors, this emphasis on regulatory and manufacturing capabilities in Europe suggests Forge is positioning itself as a key contract partner in a growing regional gene therapy market.
The post suggests that Forge aims to help developers manage increasingly complex regulatory requirements, which could enhance client stickiness and expand recurring revenue opportunities. If the company continues to build a reputation around EU regulatory expertise, it could strengthen its competitive differentiation versus other contract development and manufacturing organizations in the gene therapy space.